Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT07137871
What this trial is testing

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

Who this might be right for
Breast Cancer Metastatic
The University of Texas Health Science Center at San Antonio 35
Testing effectiveness (Phase 2)Study completedNCT02252887
What this trial is testing

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Who this might be right for
Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center 45
Testing effectiveness (Phase 2)UnknownNCT02422199
What this trial is testing

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 128
Not applicableLooking for participantsNCT04968964
What this trial is testing

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

Who this might be right for
Breast CancerCancer of the Breast
Washington University School of Medicine 55
Large-scale testing (Phase 3)Looking for participantsNCT07413939
What this trial is testing

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Who this might be right for
HER2-positive Breast Cancer
Hoffmann-La Roche 650
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Ended earlyNCT00777335
What this trial is testing

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Translational Research in Oncology 4
Testing effectiveness (Phase 2)Looking for participantsNCT05846789
What this trial is testing

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Who this might be right for
Metastatic Breast CancerTriple Negative Breast CancerEstrogen-receptor-low Breast Cancer+1 more
Kathy Miller 168
Not applicableStudy completedNCT05149014
What this trial is testing

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo France 306
Not applicableLooking for participantsNCT06551116
What this trial is testing

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast Cancer
Abramson Cancer Center at Penn Medicine 200
Testing effectiveness (Phase 2)Study completedNCT03321981
What this trial is testing

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Who this might be right for
Breast Cancer Metastatic
Merus B.V. 105
Not applicableEnded earlyNCT03786107
What this trial is testing

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

Who this might be right for
Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer
Puma Biotechnology, Inc. 1,583
Post-approval studies (Phase 4)Study completedNCT03355157
What this trial is testing

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Who this might be right for
Metastatic Breast Cancer
GBG Forschungs GmbH 130
Testing effectiveness (Phase 2)Ended earlyNCT03248492
What this trial is testing

DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

Who this might be right for
Breast Cancer
Daiichi Sankyo 253
Early research (Phase 1)Study completedNCT03854903
What this trial is testing

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Who this might be right for
Metastatic Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor Positive Breast Cancer
Georgetown University 19
Testing effectiveness (Phase 2)Ended earlyNCT05954143
What this trial is testing

Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2-positive Breast Cancer
Bolt Biotherapeutics, Inc. 11
Testing effectiveness (Phase 2)Looking for participantsNCT07065435
What this trial is testing

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

Who this might be right for
HER2 + Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 74
Large-scale testing (Phase 3)Active Not RecruitingNCT02947685
What this trial is testing

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Who this might be right for
HER-2 Positive Breast CancerEstrogen Receptor Positive Breast Cancer
Alliance Foundation Trials, LLC. 518
Large-scale testing (Phase 3)Active Not RecruitingNCT04784715
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Who this might be right for
Breast Cancer; HER2-positive; Metastatic
AstraZeneca 1,157
Testing effectiveness (Phase 2)Study completedNCT00847171
What this trial is testing

Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Next Page